Analysts’ recommendations and target price
Wall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher than the company’s closing price on March 18. The consensus analyst recommendation for the stock is a “buy.” Although analysts first revised the company’s target price downward from $145.50 in January to $144.22 in February, they raised it to $144.71 in March.
To learn about the key growth drivers and risks for Johnson & Johnson this year, read Here Are Some Possible Headwinds and Tailwinds for JNJ in 2019.
Of the 18 analysts covering Johnson & Johnson, four analysts have given it “strong buys,” five have given it “buys,” eight have given it “holds,” and only one has given it a “sell.” The highest target price estimate for the company is $160, and the lowest is $123.
On March 18, Johnson & Johnson closed at $137.17, 0.31% lower than its previous closing price, 15.64% higher than its 52-week low of $118.62, and 7.93% lower than its 52-week high of $148.99. The company’s market cap is $366.42 billion.
Based on its closing price on March 18, Johnson & Johnson has reported returns of -1.00% in the last week, 2.13% in the last month, and -7.22% in the last quarter. The company has reported returns of -1.94% in the last half year, 3.09% in the last year, and 6.29% year-to-date.
Revenue and EPS estimates
Analysts expect Johnson & Johnson’s revenue to see YoY (year-over-year) changes of -1.94% to $19.62 billion in the first quarter, -1.93% to $20.43 billion in the second quarter, -0.96% to $20.15 billion in the third quarter, and 2.33% to $20.87 billion in the fourth quarter of 2019. Analysts also expect the company’s non-GAAP (generally accepted accounting principles) EPS to see YoY rises of 2.73% to $2.12 in the first quarter, 9.65% to $2.30 in the second quarter, 4.51% to $2.14 in the third quarter, and 2.28% to $2.01 in the fourth quarter.
Analysts expect Johnson & Johnson’s revenues to see YoY changes of -0.50% to $81.17 billion in 2019, 4.18% to $84.56 billion in 2020, and 4.37% to $88.26 billion in 2021. Analysts also expect the company’s non-GAAP EPS to see YoY rises of 4.93% to $8.58 in 2019, 5.76% to $9.08 in 2020, and 7.55% to $9.76 in 2021.